Advanced Genomic Cancer Testing

The only genomic test proven to predict a patient’s individual benefit from chemotherapy. For patients with early-stage, ER-positive, HER2-negative, node-negative, and node-positive (1-3) breast cancer, the Oncotype DX Breast Recurrence Score quantifies the risk of distant recurrence and the likelihood of chemotherapy benefit.

Altera™ uses a combined whole-exome and whole-transcriptome sequencing approach, delivering a deeper understanding of each cancer’s unique genomic signature. It identifies clinically relevant biomarkers that can help guide patient management, from selecting targeted therapies and immunotherapies to matching patients with clinical trials. When used alongside Signatera™ for recurrence monitoring, Altera™ helps maximise patient insights while conserving tissue for comprehensive, actionable results.

DCISionRT is a precision medicine test for women diagnosed with DCIS or Stage 0 breast cancer who are treated with breast-conserving surgery. It assesses a woman’s 10-year risk of DCIS recurrence or development of invasive breast cancer and provides predictive information on the benefit of radiation therapy in reducing those risks.